Formulary Group work programme


Forthcoming submissions 2015

This list is indicative and may be subject to change.

Atomoxetine - SMC 909/13 - in progress. (Indication: treatment of attention-deficit/hyperactivity disorder (ADHD) in adults as part of a comprehensive treatment programme).

Apixaban - SMC 1029/15 - Formulary Group advice will be published by 31st March 2015. (Indication: treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and prevention of recurrent DVT and PE in adults).

Dabrafenib - SMC 1023/15 - Formulary Group advice will be published by 31st March 2015. (Indication: monotherapy treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation).

Fosfomycin - SMC 1033/15 - in progress. (Indication: for the treatment of the following infections in adults and children including neonates:
- Acute osteomyelitis
- Complicated urinary tract infections
- Nosocomial lower respiratory tract infections
- Bacterial meningitis
- Bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above).

Idelalisib - SMC 1026/15 - Formulary Group advice will be published by 31st March 2015. (Indication: in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)).

Infliximab (Remsima®) - SMC 1006/14 - Formulary Group advice will be published by 31st March 2015.(Indication: rheumatoid arthritis: in combination with methotrexate).

Infliximab (Inflectra®) - SMC 1007/14 - Formulary Group advice will be published by 31st March 2015. (Indication: rheumatoid arthritis: in combination with methotrexate).  

Ipilimumab - SMC 997/14 - Formulary Group advice will be published by 31st March 2015. (Indication: treatment of advanced (unresectable or metastatic) melanoma in adults (first-line use)).

Ledipasvir/sofosbuvir (Harvoni®) - SMC 1030/15 - Formulary Group advice will be published by 31st March 2015. (Indication: treatment of chronic hepatitis C (CHC) in adults).

Nalmefene - SMC 917/13 - Formulary Group advice will be published by 31st March 2015. (Indication: for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking risk level (DRL), without physical withdrawal symptoms, and who do not require immediate detoxification).

Nepafenac - SMC 813/12 - in progress. (Indication: reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients).

Ondanestron - SMC 912/13 - in progress. (Indication: in adults: prophylaxis and treatment of acute and delayed nausea and vomiting induced by chemotherapy, and radiotherapy. Prophylaxis and treatment of post-operative nausea and vomiting.
In paediatric populations: management of chemotherapy-induced nausea and vomiting in children aged ≥6 months and prophylaxis and treatment of post-operative nausea and vomiting (PONV) in children aged ≥4 years).

Peginterferon beta 1a - SMC 1018/14 - Formulary Group advice will be published by 31st March 2015. (Indication: in adult patients for the treatment of relapsing remitting multiple sclerosis).

Ruxolitinib - SMC 867/13 - Formulary Group advice will be published by 31st March 2015. (Indication: the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis).

Publication schedule

This web page is updated monthly, within 7 working days of publication of SMC advice.

END

« Previous: Formulary Group | Top | Next: Formulary Group decisions index »